InfectionsSexually Transmitted DiseasesAIDS/HIVAIDS/HIV Sexually Transmitted DiseasesDoctorsGeneral HealthPrescription DrugsInfectious DiseaseInflammationStdPublic HealthDrugs
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Aug. 9, 2012 (HealthDay News) -- Doctors should consider prescribing the HIV prevention pill Truvada to their heterosexual patients who are at high risk for the virus, not just high-risk gay and bisexual men, experts from the U.S. Centers for Disease Control and Prevention said on Thursday.
The CDC announcement comes on the heels of recent research that revealed that 27 percent of new HIV cases in the United States in 2009 involved heterosexuals who were not injection-drug users. Based on these findings, government health officials advised that the once-a-day pill can also help prevent HIV infection in high-risk heterosexual men and women.
Last month, the U.S. Food and Drug Administration approved the use of Truvada for the reduction of risk for sexual acquisition of HIV infection among adults, including both heterosexuals and gay or bisexual men.
The newly updated CDC guidelines are an attempt to prevent the spread of HIV through heterosexual sex. U.S. health officials noted that Truvada, when taken regularly in combination with other preventative measures, can offer an additional layer of protection for heterosexual men and women at high risk for infection with the virus that causes AIDS.
The CDC is not recommending Truvada for all heterosexuals who are sexually active, and they stress that the condom remains a good first line of defense against HIV. However, couples in which one member is HIV-positive and the other is uninfected may look to Truvada as an option in addition to condom use. And if such a couple wanted to have a baby, Truvada might be a good option in that case as well, Dr. Dawn Smith, the CDC physician who was lead author of the new guidance, told the Associated Press.
CDC officials advised, however, that doctors who consider prescribing the anti-HIV drug for their high-risk heterosexual patients should be certain these men and women are not already infected with the virus. Doctors should also continuously monitor their patients' HIV status and provide this high-risk group with regular counseling on other ways to prevent the spread of HIV, such as practicing safe sex.
High-risk heterosexuals are "not a portion of the epidemic we want to ignore," Smith, of the CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, told AP.
When used as a preventive, the daily pill costs between $6,000 and $12,000 a year, although some private insurers and Medicaid programs may cover it, Smith added.
Although Truvada, made by Gilead Sciences, has been approved since 2004, the CDC authors noted that guidelines on the use of the drug will be updated as more information on its efficacy and safety for all groups at risk for HIV becomes available from additional studies.
In the United States, an estimated 48,100 new HIV infections occurred in 2009, the authors noted in background information in the report, which was published in the Aug. 10 issue of the CDC's Morbidity and Mortality Weekly Report.
Find out more about HIV/AIDS at AIDS.gov.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Read this Next
Other Trending Articles